Diese Seite wurde automatisch übersetzt und die Genauigkeit der Übersetzung wird nicht garantiert. Bitte wende dich an die englische Version für einen Quelltext.

CHina Adrenal Venous saMPling InvestigatiON (CHAMPION)

6. November 2026 aktualisiert von: Hui DONG, Chinese Academy of Medical Sciences, Fuwai Hospital

China Adrenal Venous Sampling Investigation: Eine nationale multizentrische Studie

Primary aldosteronism (PA) is a major cause of secondary hypertension, yet its optimal diagnosis and management remain challenging. This study comprehensively evaluates adrenal venous sampling (AVS), addressing key clinical, technical, and methodological issues, and aims to clarify the relationship between AVS-guided management and long-term clinical and biochemical outcomes to optimize patient care and prognosis.

Studienübersicht

Detaillierte Beschreibung

Primary aldosteronism (PA) is one of the most common causes of secondary hypertension, yet its optimal diagnostic and therapeutic strategies remain challenging. Adrenal venous sampling (AVS) is regarded as the gold standard for subtype differentiation; however, important clinical, technical, and methodological issues have not been systematically addressed. This study is designed to comprehensively evaluate AVS and its clinical implications, aiming to elucidate the relationship between AVS-guided diagnosis and management of PA and long-term clinical and biochemical outcomes, while refining AVS protocols, standardizing clinical practice, optimizing therapeutic decision-making, and ultimately improving patient management and prognosis.

Studientyp

Beobachtungs

Einschreibung (Geschätzt)

5000

Kontakte und Standorte

Dieser Abschnitt enthält die Kontaktdaten derjenigen, die die Studie durchführen, und Informationen darüber, wo diese Studie durchgeführt wird.

Studienkontakt

Studieren Sie die Kontaktsicherung

Studienorte

    • Anhui
      • Hefei, Anhui, China, 230036
        • Rekrutierung
        • The first affiliated hospital of USTC
        • Kontakt:
        • Hauptermittler:
          • Xiangyong Kong, PhD
    • Beijing Municipality
      • Beijing, Beijing Municipality, China, 100034
        • Rekrutierung
        • Peking University First Hospital
        • Hauptermittler:
          • Wei Ma, MD
        • Kontakt:
      • Beijing, Beijing Municipality, China, 100044
        • Rekrutierung
        • Peking University People's Hospital
        • Kontakt:
        • Hauptermittler:
          • Jing Liu, MD
      • Beijing, Beijing Municipality, China, 100029
        • Rekrutierung
        • China-Japan Friendship Hospital
        • Hauptermittler:
          • Wuqiang Che, MD
        • Kontakt:
      • Beijing, Beijing Municipality, China, 100022
        • Rekrutierung
        • Chuiyangliu Hospital affiliated to Tsinghua University
        • Hauptermittler:
          • Lin Pi, MD
        • Kontakt:
      • Beijing, Beijing Municipality, China, 100037
        • Rekrutierung
        • Fuwai Hospital, National Center for Cardiovascular Disease, Chinese Academy of Medical Sciences and Peking Union Medical College
        • Hauptermittler:
          • Hui Dong, MD
        • Kontakt:
        • Kontakt:
      • Beijing, Beijing Municipality, China, 101100
        • Rekrutierung
        • Beijing Luhe Hospital, Capital Medical University
        • Kontakt:
        • Hauptermittler:
          • Dong Zhao, MD, PhD
    • Chongqing Municipality
      • Chongqing, Chongqing Municipality, China, 400000
        • Rekrutierung
        • Chongqing University Central Hospital
        • Hauptermittler:
          • Dongying Zhang, MD
        • Kontakt:
      • Chongqing, Chongqing Municipality, China, 401147
        • Rekrutierung
        • Chongqing General Hospital
        • Hauptermittler:
          • Rui He, MM
        • Kontakt:
      • Chongqing, Chongqing Municipality, China, 404100
        • Rekrutierung
        • People's Hospital Affiliated to ChongqingThree Gorges Medical college
        • Hauptermittler:
          • Xianhu Luo, MD
        • Kontakt:
    • Fujian
      • Fuzhou, Fujian, China, 0591-87982222
        • Rekrutierung
        • First Affiliated Hospital, Fujian Medical University, Fuzhou, China,
        • Kontakt:
        • Hauptermittler:
          • Feng Peng, MD
      • Xiamen, Fujian, China, 361016
        • Rekrutierung
        • Cardiovascular Hospital Xiamen University
        • Hauptermittler:
          • Tao Ye, MD
        • Kontakt:
    • Gansu
      • Lanzhou, Gansu, China, 730000
        • Rekrutierung
        • Lanzhou University Second Hospital
        • Hauptermittler:
          • Wei Liang, MD
        • Kontakt:
    • Guangdong
      • Foshan, Guangdong, China, 528211
        • Rekrutierung
        • The Forth People's Hosptal of Nanhai District of Foshan City
        • Hauptermittler:
          • Yayan Han, MD
        • Kontakt:
      • Guangzhou, Guangdong, China, 510080
        • Rekrutierung
        • Guangdong Provincial People's Hospital (Guangdong Academy of Medical Sciences)
        • Hauptermittler:
          • Yingqing Feng, MD
        • Kontakt:
      • Shenzhen, Guangdong, China, 518000
        • Rekrutierung
        • Fuwai Hospital Chinese Academy of Medical Sciences, Shenzhen
        • Kontakt:
        • Hauptermittler:
          • Jianqiong Kong, MD
      • Shenzhen, Guangdong, China, 518112
        • Rekrutierung
        • Shenzhen Third People's Hospital,Shenzhen, Guangdong Province 518112, China
        • Kontakt:
        • Hauptermittler:
          • Zhenzhong Zheng, MD, PhD
      • Shenzhen, Guangdong, China, 518116
        • Rekrutierung
        • Shenzhen Dapeng New District Kuiyong People's Hospital
        • Hauptermittler:
          • Tongqing Lu, MD
        • Kontakt:
    • Guangxi
      • Nanning, Guangxi, China, 530000
        • Rekrutierung
        • The First Affiliated Hospital of Guangxi Medical University
        • Hauptermittler:
          • Jiangnan Huang, MD
        • Kontakt:
      • Nanning, Guangxi, China, 530007
        • Rekrutierung
        • The Second Affliated Hospital Of GuangXi Medical Univesity
        • Kontakt:
        • Hauptermittler:
          • Houfa Ning, MM
      • Nanning, Guangxi, China, 547000
        • Rekrutierung
        • Nanning Third People's Hospital
        • Kontakt:
          • Yongqi Xiao, MBBS
          • Telefonnummer: 07713394390
        • Hauptermittler:
          • Yongqi Xiao, MBBS
    • Guizhou
      • Guiyang, Guizhou, China, 550004
        • Rekrutierung
        • The Affiliated Hospital of Guizhou Medical University
        • Kontakt:
        • Hauptermittler:
          • Zhangrong Chen, MD
      • Guiyang, Guizhou, China, 550002
        • Rekrutierung
        • Guizhou Provincial People's Hospital, Guiyang, Guizhou 550002, China.
        • Kontakt:
        • Hauptermittler:
          • Fang Song, MD
      • Kaili, Guizhou, China, 556000
        • Rekrutierung
        • The Second Affiliated Hospital Of Guizhou Medical University
        • Hauptermittler:
          • Yumei Xiang, MD
        • Kontakt:
    • Hainan
      • Haikou, Hainan, China, 570311
        • Rekrutierung
        • Hainan General Hospital, Department of Endocrinology
        • Kontakt:
        • Hauptermittler:
          • Haiyu Zhang, MM
      • Hainan, Hainan, China, 570311
        • Rekrutierung
        • Hainan General Hospital, Department of Cardiology
        • Kontakt:
        • Hauptermittler:
          • Wang Liao, MD
    • Hebei
      • Tangshan, Hebei, China, 063000
        • Rekrutierung
        • Tangshan hongci Hospital
        • Hauptermittler:
          • Guijuan Zhang, MD
        • Kontakt:
    • Heilongjiang
      • Harbin, Heilongjiang, China, 150086
        • Rekrutierung
        • The Second Affiliated Hospital of Harbin Medical University
        • Kontakt:
        • Hauptermittler:
          • Shuo Zhang, MD
      • Harbin, Heilongjiang, China, 150001
        • Rekrutierung
        • The First Affiliated Hospital of Harbin Medical University
        • Hauptermittler:
          • Dechao Zhao, MD
        • Kontakt:
    • Henan
      • Kaifeng, Henan, China, 475002
        • Rekrutierung
        • Kai Feng the Peoples Hospital
        • Kontakt:
        • Hauptermittler:
          • Qingli Pan, MD
      • Zhengzhou, Henan, China, 450052
        • Rekrutierung
        • The First Affiliated Hospital of Zhengzhou University
        • Kontakt:
        • Hauptermittler:
          • Youyou Du, MD
      • Zhengzhou, Henan, China, 450003
        • Rekrutierung
        • Henan Provincial People's Hospital
        • Hauptermittler:
          • Min Liu, MD
        • Kontakt:
      • Zhengzhou, Henan, China, 450000
        • Rekrutierung
        • Fuwai Central China Cardiovascular Hospital
        • Hauptermittler:
          • Qiuping Zhao, PhD
        • Kontakt:
      • Zhengzhou, Henan, China, 450018
        • Rekrutierung
        • Zhengzhou Yihe Hospital
        • Kontakt:
        • Hauptermittler:
          • Liang An, MD
      • Zhengzhou, Henan, China, 450007
        • Rekrutierung
        • Zhengzhou Central Hospital Affiliated to Zhengzhou University
        • Hauptermittler:
          • Shuhua Yu, MM
        • Kontakt:
      • Zhoukou, Henan, China, 466000
        • Rekrutierung
        • Zhoukou Central Hospital
        • Hauptermittler:
          • Baogong Wang, MD
        • Kontakt:
    • Hubei
      • Wuhan, Hubei, China, 430060
        • Rekrutierung
        • Renmin Hospital of Wuhan University
        • Kontakt:
        • Hauptermittler:
          • Hongxin Xu, MD
      • Xiangyang, Hubei, China, 441021
        • Rekrutierung
        • Xiangyang Central Hospital, Affiliated Hospital of Hubei University of Arts and Science
        • Kontakt:
        • Hauptermittler:
          • Qingan Li, MD
      • Yichang, Hubei, China, 43000
        • Rekrutierung
        • Yichang Central People's Hospital
        • Hauptermittler:
          • Yunbo Lv, MD
        • Kontakt:
    • Hunan
      • Zhuzhou, Hunan, China, 412000
        • Rekrutierung
        • Zhuzhou Hospital Affiliated to Xiangya School of Medicine,Central South University
        • Kontakt:
          • Liang Tang, MBBS
          • Telefonnummer: 0733-28561703
        • Hauptermittler:
          • Liang Tang, MBBS
    • Jiangsu
      • Xuzhou, Jiangsu, China, 221009
        • Rekrutierung
        • Xuzhou Central Hospital, Jiangsu
        • Kontakt:
        • Hauptermittler:
          • Hongyun Ruan, MD
    • Jiangxi
      • Ganzhou, Jiangxi, China, 341000
        • Rekrutierung
        • The First Affiliated Hospital of Gannan Medical University
        • Kontakt:
        • Hauptermittler:
          • Jiayuan Yuan, MD
      • Nanchang, Jiangxi, China, 330006
        • Rekrutierung
        • Second Affiliated Hospital of Nanchang University
        • Kontakt:
        • Hauptermittler:
          • Yifei Dong, MD, PhD
      • Nanchang, Jiangxi, China, 330038
        • Rekrutierung
        • Jiangxi Provincial People's Hospital (The First Affiliated Hospital of Nanchang Medical College)
        • Hauptermittler:
          • Haohang Ruan, MBBS
        • Kontakt:
          • Haohang Ruan, MBBS
          • Telefonnummer: 0791-87721036
    • Jilin
      • Changchun, Jilin, China, 130021
        • Rekrutierung
        • The First Hospital of Jilin University
        • Kontakt:
        • Hauptermittler:
          • Wei Zhao, MD
      • Changchun, Jilin, China, 130051
        • Rekrutierung
        • Jilin Province FAW General Hospital
        • Hauptermittler:
          • Wenhai Wang, MM
        • Kontakt:
    • Liaoning
      • Dalian, Liaoning, China, 116001
        • Rekrutierung
        • Affilated Zhongshan Hospital of Dalian University
        • Kontakt:
        • Hauptermittler:
          • Minglian Gong, MD
      • Dalian, Liaoning, China, 116011
        • Rekrutierung
        • Frist Aiffiliated Hospital of Dalian Medical University
        • Hauptermittler:
          • Yinong Jiang, MD
        • Kontakt:
      • Dalian, Liaoning, China, 116027
        • Rekrutierung
        • The second hospital of Dalian Medical University
        • Kontakt:
        • Hauptermittler:
          • Nan Niu, MD
    • Neimenggu
      • Ulanhot, Neimenggu, China, 137400
        • Rekrutierung
        • Inner Mongolia Xing'an League People's Hospital
        • Kontakt:
        • Hauptermittler:
          • Tao Guo, MM
    • Ningxia
      • Yinchuan, Ningxia, China, 750000
        • Rekrutierung
        • The First People's Hospital of Yinchuan
        • Kontakt:
        • Hauptermittler:
          • Fang Chen, PhD
    • Qinghai
      • Xining, Qinghai, China, 810001
        • Rekrutierung
        • Qinghai University Affiliated Hospital
        • Kontakt:
        • Hauptermittler:
          • Ming Ren, MM
      • Xining, Qinghai, China, 810000
        • Rekrutierung
        • Qinghai Province Cardiovascular and Cerebrovascular Disease Specialist Hospital
        • Kontakt:
        • Hauptermittler:
          • Xiaozhou Wang, MD
    • Shandong
      • Jinan, Shandong, China, 250012
        • Rekrutierung
        • Qilu Hospital of Shandong University
        • Hauptermittler:
          • Peili Bu, MD
        • Kontakt:
      • Jinan, Shandong, China, 250013
        • Rekrutierung
        • Central Hospital Affiliated to Shandong First Medical University
        • Kontakt:
        • Hauptermittler:
          • Rui Xu, MD, PhD
      • Jinan, Shandong, China, 250000
        • Rekrutierung
        • the Second Hospital, Cheeloo College of Medicine, Shandong University
        • Kontakt:
        • Hauptermittler:
          • Qinghai Wang, MD
      • Liaocheng, Shandong, China, 252200
        • Rekrutierung
        • People's Hospital of Donga County, Shandong Province
        • Hauptermittler:
          • Xiaoli Wang, MD
        • Kontakt:
      • Qingdao, Shandong, China, 266000
        • Rekrutierung
        • Qingdao Hospital University of Health and Rehabilitation Sciences (Qingdao Municipal Hospital)
        • Kontakt:
        • Hauptermittler:
          • Nan Jia, MD
    • Shanghai Municipality
      • Shanghai, Shanghai Municipality, China, 200025
        • Rekrutierung
        • Shanghai Institute of Hypertension, Ruijin Hospital, Shanghai Jiaotong University School of Medicine
        • Kontakt:
        • Hauptermittler:
          • Jianzhong Xu, MD, PhD
      • Shanghai, Shanghai Municipality, China, 200062
        • Rekrutierung
        • Shanghai Putuo District Central Hospital
        • Hauptermittler:
          • Zongjun Liu, MD
        • Kontakt:
      • Shanghai, Shanghai Municipality, China, 200080
        • Rekrutierung
        • Shanghai General Hospital ( originally named Shanghai First People's Hospital), Shanghai Jiao Tong University School of Medicine
        • Kontakt:
        • Hauptermittler:
          • Zhi Zhang, MD
    • Shanxi
      • Taiyuan, Shanxi, China, 030001
        • Rekrutierung
        • the second hospital of ShanXi medical unversity
        • Hauptermittler:
          • Bin Yang, MD
        • Kontakt:
      • Xi’an, Shanxi, China, 710018
        • Rekrutierung
        • Xi'an People's Hospital
        • Kontakt:
        • Hauptermittler:
          • Kang Cheng, MD, PhD
    • Sichuan
      • Chengdu, Sichuan, China, 611130
        • Rekrutierung
        • Chengdu Fifth People's Hospital
        • Hauptermittler:
          • Mingjian Lang, MD
        • Kontakt:
      • Chengdu, Sichuan, China, 610500
        • Rekrutierung
        • The First Affiliated Hospital of Chengdu Medical College
        • Hauptermittler:
          • Peijian Wang, MD
        • Kontakt:
      • Chengdu, Sichuan, China, 610031
        • Rekrutierung
        • The Affiliated Hospital of Southwest Jiaotong University, The Third People's Hospital of Chengdu, Chengdu, China
        • Hauptermittler:
          • Zhen Zhang, MD
        • Kontakt:
    • Tianjin Municipality
      • Tianjin, Tianjin Municipality, China, 300052
        • Rekrutierung
        • Tianjin Medical University General Hospital
        • Hauptermittler:
          • Dianxun Fu, MD
        • Kontakt:
      • Tianjin, Tianjin Municipality, China, 300211
        • Rekrutierung
        • The Second Hospital of Tianjin Medical University
        • Hauptermittler:
          • Changle Liu, MD
        • Kontakt:
      • Tianjin, Tianjin Municipality, China, 300457
        • Rekrutierung
        • TEDA International Cardiovascular Hospital
        • Kontakt:
        • Hauptermittler:
          • Weiqiang Wang, MM
    • Tibet
      • Chamdo, Tibet, China, 854000
        • Rekrutierung
        • Changdu People's Hospital of Tibet
        • Kontakt:
          • Rui Xiang, MD
          • Telefonnummer: 0895-4821745
        • Hauptermittler:
          • Rui Xiang, MD
    • Xinjiang
      • Yining, Xinjiang, China, 835000
        • Rekrutierung
        • Yili Kazak Autonomous Prefecture Friendship Hospital
        • Kontakt:
        • Hauptermittler:
          • Wei Li, MBBS
      • Ürümqi, Xinjiang, China, 830001
        • Rekrutierung
        • Xinjiang Uygur Autonomous Region People's Hospital
        • Kontakt:
        • Hauptermittler:
          • Guoliang Wang, PhD
    • Yunnan
      • Kunming, Yunnan, China, 650031
        • Rekrutierung
        • The First Affiliated Hospital of Kunming Medical University
        • Kontakt:
        • Hauptermittler:
          • Lihua Zhang, PhD
      • Kunming, Yunnan, China, 650102
        • Rekrutierung
        • Fuwai Yunnan Cardiovascular Hospital
        • Hauptermittler:
          • Zihong Guo, MD
        • Kontakt:
      • Kunming, Yunnan, China, 650051
        • Rekrutierung
        • Yan'an Affiliated Hospital of Kunming Medical University
        • Kontakt:
        • Hauptermittler:
          • Yan He, MD
    • Zhejiang
      • Hangzhou, Zhejiang, China, 310000
        • Rekrutierung
        • Zhejiang Hospital
        • Hauptermittler:
          • Yimin Tang, MD
        • Kontakt:

Teilnahmekriterien

Forscher suchen nach Personen, die einer bestimmten Beschreibung entsprechen, die als Auswahlkriterien bezeichnet werden. Einige Beispiele für diese Kriterien sind der allgemeine Gesundheitszustand einer Person oder frühere Behandlungen.

Zulassungskriterien

Studienberechtigtes Alter

18 Jahre und älter (Erwachsene, Älterer Erwachsener)

Akzeptiert gesunde Freiwillige

Nein

Studienberechtigte Geschlechter

Alle

Probenahmeverfahren

Nicht-Wahrscheinlichkeitsprobe

Studienpopulation

All patients with confirmed primary aldosteronism underwent adrenal venous sampling.

Beschreibung

Inclusion Criteria:

  1. Patients with confirmed primary aldosteronism;
  2. Patients undergoing adrenal venous sampling for subtype classification of primary aldosteronism.

Exclusion Criteria:

  1. Severe comorbidity, including stroke, myocardial infarction, heart failure, severe valvular heart disease, liver cirrhosis, and metastatic tumor within the previous 3 months;
  2. An estimated glomerular filtration rate <45 ml/min/1.73 m2, or serum creatinine >176 μmol/L;
  3. Patients who refuse adrenalectomy;
  4. Suspected of having an adrenocortical carcinoma;
  5. Allergy to contrast agent;
  6. Pregnant, nursing, or planning to become pregnant

Studienplan

Dieser Abschnitt enthält Einzelheiten zum Studienplan, einschließlich des Studiendesigns und der Messung der Studieninhalte.

Wie ist die Studie aufgebaut?

Designdetails

  • Beobachtungsmodelle: COHORT
  • Zeitperspektiven: OTHER

Kohorten und Interventionen

Gruppe / Kohorte
Intervention / Behandlung
Adrenal Venous Sampling

Patients with Primary Aldosteronism (PA) undergoing Adrenal Venous Sampling via antecubital approach or femoral approach to discriminate PA forms with unilateral from bilateral excess aldosterone production.

Patients with Primary Aldosteronism (PA) undergoing Adrenal Venous Sampling via antecubital approach or femoral approach to discriminate PA forms with unilateral from bilateral excess aldosterone production.

Was misst die Studie?

Primäre Ergebnismessungen

Ergebnis Maßnahme
Maßnahmenbeschreibung
Zeitfenster
Major adverse cardiovascular events (MACE) at 1-year follow-up
Zeitfenster: 1 year after AVS procedure

Incidence of major adverse cardiovascular events (MACE) at 1-year follow-up, including stroke, heart failure, severe arrhythmias, renal failure, myocardial infarction, and death.

1 year after AVS procedure

Sekundäre Ergebnismessungen

Ergebnis Maßnahme
Maßnahmenbeschreibung
Zeitfenster
The success rate of left adrenal venous sampling
Zeitfenster: At AVS procedure

Successful sampling will be defined by high selectivity index (cortisol in the adrenal vein/cortisol in inferior vena cava >2 without ACTH simulation)

At AVS procedure
The success rate of right adrenal venous sampling
Zeitfenster: At AVS procedure

Successful sampling will be defined by high selectivity index (cortisol in the adrenal vein/cortisol in inferior vena cava >2 without ACTH simulation)

At AVS procedure
The success rate of bilateral adrenal venous sampling
Zeitfenster: At AVS procedure

Successful sampling will be defined by high selectivity index (cortisol in the adrenal vein/cortisol in inferior vena cava >2 without ACTH simulation)

At AVS procedure
Selection of intraoperative catheter
Zeitfenster: At AVS procedure

Types of catheter at the time of Adrenal Venous Sampling via antecubital approach or femoral approach

At AVS procedure
Time of the procedure
Zeitfenster: At AVS procedure

Time of the procedure

At AVS procedure
Time of fluoroscopy
Zeitfenster: At AVS procedure

Time of fluoroscopy

At AVS procedure
The contrast agent dosage
Zeitfenster: At AVS procedure

The contrast agent dosage

At AVS procedure
the incidence of complications
Zeitfenster: 1 week after AVS procedure

Complications related to adrenal vein cannulations (adrenal vein hematoma, inferior vena cava dissection, puncture site hematoma, etc)

1 week after AVS procedure
the cost of the procedure
Zeitfenster: At AVS procedure

the cost of the procedure

At AVS procedure
Change in 24-hour ambulatory systolic blood pressure
Zeitfenster: At 1, 3, 6, 12, and 18 months; and 2, 3, 4, 5, and 10 years after treatment

The difference in average systolic blood pressure measured by 24-hour ambulatory blood pressure monitoring (ABPM) between baseline and each follow-up time point.

At 1, 3, 6, 12, and 18 months; and 2, 3, 4, 5, and 10 years after treatment
Change in 24-hour ambulatory diastolic blood pressure
Zeitfenster: At 1, 3, 6, 12, and 18 months; and 2, 3, 4, 5, and 10 years after treatment

The difference in average diastolic blood pressure measured by 24-hour ambulatory blood pressure monitoring (ABPM) bewteen baseline and each follow-up time point.

At 1, 3, 6, 12, and 18 months; and 2, 3, 4, 5, and 10 years after treatment
Change in office systolic blood pressure
Zeitfenster: At 1, 3, 6, 12, and 18 months; and 2, 3, 4, 5, and 10 years after treatment

The difference in systolic blood pressure measured during clinic visits (office blood pressure) between baseline and each follow-up time point

At 1, 3, 6, 12, and 18 months; and 2, 3, 4, 5, and 10 years after treatment
Change in office diastolic blood pressure
Zeitfenster: At 1, 3, 6, 12, and 18 months; and 2, 3, 4, 5, and 10 years after treatment

The difference in diastolic blood pressure measured during clinic visits (office blood pressure) between baseline and each follow-up time point

At 1, 3, 6, 12, and 18 months; and 2, 3, 4, 5, and 10 years after treatment
Change in antihypertensive medication burden
Zeitfenster: At 1, 3, 6, 12, and 18 months; and 2, 3, 4, 5, and 10 years after treatment

The change in the number and/or dosage of antihypertensive medications taken by patients between baseline and each follow-up time point

At 1, 3, 6, 12, and 18 months; and 2, 3, 4, 5, and 10 years after treatment
Change in urinary albumin-to-creatinine ratio (UACR)
Zeitfenster: At 1, 3, 6, 12, and 18 months; and 2, 3, 4, 5, and 10 years after treatment

The difference in urinary albumin-to-creatinine ratio measured at baseline and at each follow-up time point

At 1, 3, 6, 12, and 18 months; and 2, 3, 4, 5, and 10 years after treatment
Change in left ventricular mass index (LVMI)
Zeitfenster: At 1, 3, 6, 12, and 18 months; and 2, 3, 4, 5, and 10 years after treatment

The change in left ventricular mass index, as assessed by echocardiography, from baseline to each follow-up time point.

At 1, 3, 6, 12, and 18 months; and 2, 3, 4, 5, and 10 years after treatment
Change in pulse wave velocity (PWV) from baseline
Zeitfenster: At 1, 3, 6, 12, and 18 months; and 2, 3, 4, 5, and 10 years after treatment

The change in pulse wave velocity measured between baseline and each follow-up time point。

At 1, 3, 6, 12, and 18 months; and 2, 3, 4, 5, and 10 years after treatment
Clinical Outcome According to Primary Aldosteronism Surgical Outcome (PASO) Criteria
Zeitfenster: At 6, 12, and 18 months; and 2, 3, 4, 5, and 10 years after surgery

Clinical outcomes will be assessed at each follow-up visit afteradrenal surgery according to the PASO consensus criteria. Outcomes will be categorized as:

(1)Complete clinical success: normal blood pressure without the need for any antihypertensive medication. (2)Partial clinical success: improvement in blood pressure and/or a reduction in the number or dosage of antihypertensive medications. (3)Absent clinical success: no improvement in blood pressure or antihypertensive medication burden.

At 6, 12, and 18 months; and 2, 3, 4, 5, and 10 years after surgery
Biochemical Outcome According to Primary Aldosteronism Surgical Outcome (PASO) Criteria
Zeitfenster: At 6, 12, and 18 months; and 2, 3, 4, 5, and 10 years after surgery

Biochemical outcomes will be assessed at each follow-up visit after adrenal surgery according to the PASO consensus classification. Outcomes will be categorized as:(1)Complete biochemical success: normal serum potassium levels and a normalized aldosterone-to-renin ratio (ARR) without the need for potassium supplementation.(2)Partial biochemical success: improvement in biochemical parameters without full normalization.(3)Absent biochemical success: no improvement in biochemical markers compared to baseline.

At 6, 12, and 18 months; and 2, 3, 4, 5, and 10 years after surgery
Major adverse cardiovascular events (MACE)
Zeitfenster: At 6 and 18 months; and 2, 3, 4, 5, and 10 years after AVS procedure

Incidence of major adverse cardiovascular events (MACE), including stroke, heart failure, severe arrhythmias, renal failure, myocardial infarction, and death.

At 6 and 18 months; and 2, 3, 4, 5, and 10 years after AVS procedure

Mitarbeiter und Ermittler

Hier finden Sie Personen und Organisationen, die an dieser Studie beteiligt sind.

Ermittler

  • Hauptermittler: Hui Dong, MD, Fuwai Hospital, National Center for Cardiovascular Disease, Chinese Academy of Medical Sciences and Peking Union Medical College

Studienaufzeichnungsdaten

Diese Daten verfolgen den Fortschritt der Übermittlung von Studienaufzeichnungen und zusammenfassenden Ergebnissen an ClinicalTrials.gov. Studienaufzeichnungen und gemeldete Ergebnisse werden von der National Library of Medicine (NLM) überprüft, um sicherzustellen, dass sie bestimmten Qualitätskontrollstandards entsprechen, bevor sie auf der öffentlichen Website veröffentlicht werden.

Haupttermine studieren

Studienbeginn (Tatsächlich)

1. Dezember 2025

Primärer Abschluss (Geschätzt)

31. August 2029

Studienabschluss (Geschätzt)

31. August 2029

Studienanmeldedaten

Zuerst eingereicht

19. November 2025

Zuerst eingereicht, das die QC-Kriterien erfüllt hat

19. November 2025

Zuerst gepostet (Tatsächlich)

26. November 2025

Studienaufzeichnungsaktualisierungen

Letztes Update gepostet (Tatsächlich)

10. November 2026

Letztes eingereichtes Update, das die QC-Kriterien erfüllt

6. November 2026

Zuletzt verifiziert

1. November 2026

Mehr Informationen

Begriffe im Zusammenhang mit dieser Studie

Arzneimittel- und Geräteinformationen, Studienunterlagen

Studiert ein von der US-amerikanischen FDA reguliertes Arzneimittelprodukt

Nein

Studiert ein von der US-amerikanischen FDA reguliertes Geräteprodukt

Nein

Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .

Abonnieren